Deerfield Management Company »

Maxcyte shares owned by Deerfield Management Company

Quarter-by-quarter ownership of Maxcyte (MXCT) shares owned by Deerfield Management Company from 13F filings

Historical chart of Deerfield Management Company investment in Maxcyte

Tip: Access up to 7 years of quarterly data

All positions including Maxcyte held by Deerfield Management Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Maxcyte by Deerfield Management Company

Quarter filed Position value Share count Share price at filing
2023-12-31 $235k 50k 4.70

More positions owned by Deerfield Management Company

Nuvalent Inc-a (NUVL)
Glaukos Corp Note 2.750% 6/1 (Principal)
Viatris (VTRS)
Invitae Corp Debt 4.500% 3/1 (Principal)
Natera Note 2.250% 5/0 (Principal)
Catalyst Pharmaceutical Partners (CPRX)
Centene Corporation (CNC)
Brookdale Sr Living Note 2.000%10/1 (Principal)
Insmed Note 1.750% 1/1 (Principal)
Neurocrine Biosciences (NBIX)
Accolade Note 0.500% 4/0 (Principal)
Oscar Health Cl A (OSCR)
Owens & Minor (OMI)
Adapthealth Corp Common Stock (AHCO)
Springworks Therapeutics (SWTX)

View all positions for Deerfield Management Company

Top funds holding Maxcyte

Cadian Capital Management
Vanguard Group
Vitruvian Partners
Millennium Management
Portolan Capital Management
Massachusetts Financial Services
Blue Water Life Science Advisors
River & Mercantile Asset Management
Arrowpoint Asset Management
Dimensional Fund Advisors
Willis Investment Counsel
Fred Alger Management
Roubaix Capital
Lazard Asset Management
Bank of New York Mellon

View all funds holding Maxcyte